证券代码：601901 证券简称：方正证券 公告编号：2025-045 方正证券股份有限公司 第五届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司第五届监事会第十二次会议于 2025 年 11 月 26 日以现场加视频的方式在 公司会议室召开。本次会议的通知和会议资料于 2025 年 11 月 20 日以电子邮件方 式发出，本次会议由监事会主席蔡平女士召集和主持，应出席监事 3 名，实际出 席监事 3 名（蔡平女士和陈曦女士视频参会，徐国华先生现场参会），董事会秘书 列席了会议。本次会议的召集、召开程序符合《公司法》、公司《章程》的有关规 定。 经审议，本次会议形成如下决议： 审议通过了《关于不再设立监事会的议案》 监事会同意公司不再设立监事会和监事，并废止《监事会议事规则》。 此项议案需提交股东大会审议。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 方正证券股份有限公司监事会 2025 年 11 月 26 日 ...

证券代码：601901 证券简称：方正证券 公告编号：2025-046 方正证券股份有限公司 第五届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 公司第五届董事会第十九次会议于 2025 年 11 月 26 日以现场加视频的方式在公司 会议室召开。本次会议的通知和会议资料于 2025 年 11 月 20 日以电子邮件方式发出。 本次会议由董事长施华先生召集和主持，应出席董事 9 名，实际出席董事 9 名（施华 先生、张路先生、曹诗男女士、林钟高先生、柯荣富先生视频参会，姜志军先生、李 岩先生、宋洪军先生、张忠民女士现场参会），公司 3 名监事、董事候选人邹昊先生、 独立董事候选人薛军先生和部分高级管理人员列席了会议。本次会议的召集、召开程 序符合《公司法》、公司《章程》的有关规定。 经审议，本次会议形成如下决议： 一、审议通过了《关于修订公司〈章程〉及相关议事规则的议案》 董事会同意修订公司《章程》及《股东大会议事规则》《董事会议事规则》的部分 条款，其中《股东大会议事规则》更名为《股东会议事规则 ...

Market Overview - The participatory fund sector experienced a decline of 0.84% compared to the previous trading day, with Daheng Technology leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Notable gainers included: - Zhongjia Group (Code: 000039) with a closing price of 9.35, up 10.00% and a trading volume of 1.9474 million shares, totaling 1.764 billion yuan [1] - Suzhou Gaoxin (Code: 600736) closed at 5.79, up 3.76% with a trading volume of 590,000 shares, totaling 345 million yuan [1] - Daheng Technology (Code: 600288) was the biggest loser, closing at 14.69, down 2.13% with a trading volume of 86,400 shares, totaling 129 million yuan [2] Capital Flow - The participatory fund sector saw a net outflow of 732 million yuan from institutional investors, while retail investors contributed a net inflow of 574 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their participation [2] Individual Stock Capital Flow - Zhongjia Group (Code: 000039) had a net inflow of 474 million yuan from institutional investors, representing 26.86% of its trading volume [3] - Fenghuo Communication (Code: 600498) experienced a net inflow of 76.36 million yuan from institutional investors, but a net outflow of 18.29 million yuan from speculative funds [3]

Group 1: Company Overview and Market Position - The current price of MMA is approximately 9500 RMB/ton, within the mainstream price range of the industry, with stable production capacity meeting market demand [1] - The company maintains a 30% market share in the anhydride market, with an average operating rate of 90% for its anhydride facilities [2] - The catalyst business generates annual revenue of around 400 million RMB, with a net profit of approximately 60 million RMB, indicating stable operational performance [3] Group 2: Strategic Development and Future Plans - The company plans to extend its industrial chain into high-end materials, focusing on PMMA and other high-performance resin materials [1] - A strategic layout of "one area and two bases" is being developed to enhance raw material supply stability and logistics efficiency [6] - The company aims to strengthen its competitive advantage in the catalyst sector by leveraging synergies with its controlling shareholder, Shandong Energy Group [3] Group 3: Market Challenges and Responses - The anhydride market is currently facing oversupply due to slow downstream demand, particularly influenced by the real estate sector [2] - The company is focused on cost control and process optimization to maintain its competitive edge in the anhydride market [2] - The company views anti-involution policies as beneficial for the chemical industry, promoting the elimination of outdated capacity and enhancing market order [7]

Core Viewpoint - Vanke's domestic bonds experienced a significant decline, triggering temporary suspensions for multiple bonds, with some dropping over 10% [1][2] Group 1: Bond Market Reaction - Several Vanke bonds, including "21 Vanke 02," "21 Vanke 04," and "22 Vanke 02," faced temporary trading suspensions due to sharp declines [1][2] - The bond market's downturn has impacted Vanke's stock price, which fell to 5.89 CNY per share, marking a cumulative drop of over 13% in nearly 60 trading days, reaching a new low since 2015 [2] Group 2: Stock Market Impact - Vanke's Hong Kong stock price also declined from 5.94 HKD to around 4 HKD, with a reported drop of 6.04% [4] - As of 15:10, Vanke's Hong Kong stock was trading at 3.89 HKD per share [4] Group 3: Debt Management and Support - There are unconfirmed rumors regarding Vanke's debt management issues, which may be contributing to market volatility [6] - Vanke's new chairman, Huang Liping, stated that the major shareholder, Shenzhen Metro Group, will continue to support Vanke in managing liquidity risks, having provided approximately 30.8 billion CNY in shareholder loans [6] - A framework agreement was signed between Vanke and Shenzhen Metro Group for up to 22 billion CNY in shareholder loans, specifically for repaying public market bond principal and interest [7] - As of November 2, Shenzhen Metro had provided 20.373 billion CNY in loans, with Vanke having drawn 19.71 billion CNY, leaving a funding gap of 6.391 billion CNY for upcoming bond repayments [7]

Core Viewpoint - Vanke's bonds experienced a significant decline, leading to a drop in its stock price, amid concerns regarding its debt management and liquidity issues [1][3][6] Group 1: Bond Market Performance - On November 26, multiple Vanke bonds, including "21 Vanke 02," "21 Vanke 04," and "22 Vanke 02," triggered temporary trading suspensions due to sharp declines, with several bonds dropping over 10% [1] - The bond market's adjustment quickly affected the stock market, with Vanke A shares falling to 5.89 CNY per share, marking a cumulative decline of over 13% in nearly 60 trading days, the lowest since 2015 [3] Group 2: Debt Management and Support - There are unconfirmed rumors regarding Vanke's debt management issues, which may have contributed to the market volatility; Vanke has not commented on these rumors [6] - On November 20, Vanke's new chairman, Huang Liping, stated that the major shareholder, Shenzhen Metro Group, would continue to support Vanke in managing liquidity risks, having provided approximately 30.8 billion CNY in shareholder loans [6] - A framework agreement was signed on November 2, allowing Shenzhen Metro Group to provide up to 22 billion CNY in loans specifically for repaying Vanke's public market bond principal and interest [6] - As of November 2, Shenzhen Metro had already provided 20.373 billion CNY in loans, with Vanke having drawn 19.71 billion CNY, leaving a remaining loan principal of 2.29 billion CNY available for withdrawal [6] Group 3: Future Debt Obligations - According to a recent report by Founder Securities, Vanke faces significant repayment obligations, with 15.019 billion CNY in bond principal due by June 30, 2026, indicating a substantial debt gap that needs to be addressed [7] - The signing of the framework agreement does not imply that Shenzhen Metro will cease its support for Vanke, and Vanke still has some flexibility regarding its assets [7]

Group 1: Core Insights - The current wave of innovative drugs is driven by China's participation in new technologies, with advancements in ADC, bispecific antibodies, second-generation IO, and GLP-1 [1] - The global pharmaceutical transaction volume has steadily increased, with total transaction amounts rising from $56.9 billion to $187.4 billion over the past decade, while China's transaction amounts surged from $3.1 billion to $57.1 billion [1] - By 2024, China's transaction volume is expected to account for approximately 30% of global pharmaceutical transactions [1] Group 2: Sector Analysis - In oncology, the combination of IO and ADC therapies remains strong, with significant transactions in the PD-1 bispecific antibody space; the sales of Pembrolizumab are projected to reach $29.482 billion in 2024 [2] - The autoimmune disease sector is witnessing a shift as older drugs face patent expirations, with new opportunities emerging in Th2 and Th17 pathways; Dupilumab is expected to lead with $14.1 billion in sales in 2024 [2] - The cardiovascular and metabolic disease market continues to grow, with GLP-1 receptor agonists projected to exceed $50 billion in global sales in 2024 [3] Group 3: Future Technologies - New technologies such as next-generation ADCs, TCE therapies, universal/in vivo CART technologies, gene therapy, and small nucleic acid technologies are anticipated to lead future disease treatments [4]

Core Viewpoint - The recent regulatory actions against Founder Securities highlight significant compliance issues across various business lines, indicating a need for improved governance, internal controls, and compliance culture within the company [2][3][6]. Compliance Issues - Founder Securities' Guangzhou Jin Yu Er Street Securities Office received a warning letter from the Guangdong Securities Regulatory Bureau for five major violations, including sending answers to knowledge assessment questionnaires to investors and inadequate management of fund sales [2][3]. - The company has faced multiple regulatory penalties in recent years, reflecting ongoing concerns about its governance structure and internal controls [2][3]. Business Line Vulnerabilities - Violations have been particularly concentrated in branch operations, with issues such as unauthorized sales tasks assigned to unqualified personnel and breaches of client confidentiality [3][4]. - The investment banking sector has also been flagged for serious deficiencies, including inadequate due diligence and poor material review processes [3][4]. Research and Subsidiary Management - Compliance weaknesses in research operations were noted, with incidents of content leaks and unauthorized stock recommendations by analysts [4]. - Founder Securities has faced challenges in managing its subsidiaries, particularly in Hong Kong, where risk management was deemed insufficient [4]. Information Disclosure and Asset Quality - Regulatory scrutiny has increased regarding the company's financial asset investment returns and the quality of its disclosures, particularly in light of significant shareholder sell-offs and foreign capital withdrawal [5][6]. Recommendations for Improvement - To address these compliance issues, the company must enhance the authority and independence of its risk control systems and improve the integration of compliance metrics into performance evaluations [8]. - A cultural shift towards prioritizing compliance over mere performance metrics is essential for sustainable operations and regaining market trust [8].

Core Insights - The ETF market in Shanghai and Shenzhen has shown steady growth, with the total scale exceeding 57,000 billion yuan as of the end of October [1][2] - Recent regulatory changes by the China Securities Regulatory Commission (CSRC) are expected to enhance the ETF registration and listing process, potentially attracting more long-term capital into the market [1][3] Group 1: Market Overview - As of the end of October, there are 772 ETFs in the Shanghai market with a total market value of 40,847.47 billion yuan, reflecting a growth of 2.11% compared to the previous period [1] - The Shenzhen market has 559 ETFs with a total market value of 16,246.33 billion yuan, contributing to a combined ETF total of 57,093.80 billion yuan across both markets [1] Group 2: Brokerages and Trading Activity - The top 30 institutions by ETF trading volume in October include major brokerages like CITIC Securities and Huatai Securities, as well as smaller firms, indicating a stable market structure [2] - The ETF holdings among the top 30 institutions also reflect a mix of comprehensive large brokerages and specialized mid-sized firms, suggesting a trend towards differentiated operations in the ETF business [2] Group 3: Regulatory Changes - The CSRC has optimized the ETF registration and listing process by removing the requirement for a no-objection letter from the stock exchange, which is expected to reduce the administrative burden on industry participants [3] - Fund managers can now directly apply for registration for ETFs tracking mature indices, streamlining the process and enhancing market efficiency [3] - The regulatory changes aim to encourage innovation and differentiation in ETF products, addressing the issue of homogeneity in product offerings [3]

Group 1: Company Overview and Operations - Jiangsu Daye Intelligent Electric Co., Ltd. is involved in the leasing of vessels, specifically the "Jinhua 01" and "Jinhua 02" to OOS, a company with extensive operational experience in the Brazilian offshore oil and gas service market [1] - The leasing arrangement is expected to provide stable cash flow, alleviating financial pressure from high debt levels primarily associated with vessel loans [2] Group 2: Business Performance and Strategy - The company's offshore wind power business will be paused during the vessel leasing period, with future opportunities to be explored based on market conditions [2] - Revenue and gross margin for the intelligent distribution business have declined due to intensified competition and reduced contract amounts, prompting the company to focus on expanding its market presence in southern power grids and direct sales [2] - The company plans to redirect resources towards product development and market expansion in the intelligent distribution and renewable energy sectors following the vessel leasing [2] Group 3: Financial Health and Future Outlook - The company currently faces a high asset-liability ratio and elevated financial costs, but expects improvements in financial health with the leasing of vessels [2] - There are no plans to sell other assets at this time, as the leasing is anticipated to provide sufficient resources for strategic business development [2]